# A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Source: https://onco.cc/trials/nct07286266/  
OnCo record `nct07286266` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Doxorubicin, Pegylated liposomal doxorubicin, Topotecan, Gemcitabine, Pembrolizumab and Bevacizumab in ovarian cancer, run by GlaxoSmithKline, now recruiting.

## Summary

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) is a phase 3 interventional study registered as NCT07286266 by GlaxoSmithKline, with 450 participants planned, started 2026-06-18 and due to reach its primary completion in 2029-12-17. Interventions recorded: Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD), Topotecan, Gemcitabine and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07286266
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer
- Sponsor: GlaxoSmithKline
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT07286266: https://clinicaltrials.gov/study/NCT07286266

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07286266.json